Cytokinetics (CYTK) and Bayer said Tuesday they have agreed to a collaboration and license deal for the development and commercialization of the investigational drug aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy.

Under the terms of the agreement, Cytokinetics will receive an upfront payment of 50 million euros ($52.7 million) and is eligible to receive up to 90 million euros in milestone payments through commercial launch.

Cytokinetics is also eligible to receive up to 490 million euros in commercial payments based on future sales of aficamten in Japan.

Bayer will also conduct a phase 3 clinical trial of the drug in Japan while Cytokinetics will expand an ongoing phase 3 clinical trial into Japan to support the potential marketing authorization.

Hypertrophic cardiomyopathy is a disease in which the heart muscle becomes abnormally thick, limiting the heart's pumping function and resulting in reduced physical capacity.